Ning-Shao Xia Selected Research

Hepatitis E

12/2021	Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response.
1/2020	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.
1/2020	Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans.
3/2019	Application of Hepatitis E Virus-Related Markers on Samples from a Developing Country.
12/2017	Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection.
8/2015	Modeling the long-term antibody response of a hepatitis E vaccine.
3/2015	Long-term efficacy of a hepatitis E vaccine.
3/2015	A valuable antigen detection method for diagnosis of acute hepatitis E.
1/2015	The development of a recombinant hepatitis E vaccine HEV 239.
1/2015	Long-term efficacy of a hepatitis E vaccine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ning-Shao Xia Research Topics

Disease

36	Infections 01/2021 - 01/2005
20	Hepatitis E 12/2021 - 03/2004
11	Chronic Hepatitis B 03/2022 - 11/2014
10	Hepatitis B 12/2021 - 10/2012
8	Hepatitis 03/2019 - 12/2007
3	Hepatocellular Carcinoma (Hepatoma) 03/2022 - 09/2007
3	Inflammation (Inflammations) 12/2021 - 02/2018
3	Neoplasms (Cancer) 01/2021 - 09/2007
3	Persistent Infection 01/2020 - 10/2013
3	Liver Diseases (Liver Disease) 01/2015 - 10/2013
2	Triple Negative Breast Neoplasms 01/2022 - 01/2021
2	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2021
2	Liver Neoplasms (Liver Cancer) 01/2019 - 04/2012
2	Respiratory Syncytial Virus Infections 01/2019 - 01/2017
2	Viremia 12/2018 - 07/2018
2	Chronic Hepatitis (Chronic Active Hepatitis) 01/2015 - 02/2010
2	Human Influenza (Influenza) 12/2012 - 02/2011
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Pain (Aches) 12/2021
1	Fever (Fevers) 12/2021
1	Glioblastoma (Glioblastoma Multiforme) 10/2021
1	Vesicular Stomatitis 12/2020
1	COVID-19 11/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Fibrosis (Cirrhosis) 01/2019
1	Virus Diseases (Viral Diseases) 01/2017
1	Asymptomatic Infections 01/2015
1	Hepatitis A (Hepatitis, Infectious) 02/2013
1	Foot and Mouth Disease Hand (Hand, Foot, Mouth Disease) 01/2012
1	Influenza in Birds (Avian Flu) 11/2008
1	Convalescence 01/2008

Drug/Important Bio-Agent (IBA)

23	VaccinesIBA 12/2021 - 01/2005
12	AntibodiesIBA 12/2021 - 11/2006
10	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2020 - 02/2010
10	Immunoglobulin M (IgM)IBA 01/2020 - 06/2006
9	EpitopesIBA 12/2021 - 11/2006
8	Hepatitis B e AntigensIBA 12/2021 - 12/2014
8	Immunoglobulin G (IgG)IBA 12/2021 - 06/2006
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2004
8	AntigensIBA 03/2019 - 03/2004
7	hecolinIBA 01/2021 - 03/2004
6	RNA (Ribonucleic Acid)IBA 05/2020 - 06/2006
4	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 01/2015
4	Surface Antigens (Surface Antigen)IBA 01/2020 - 11/2014
4	Alanine Transaminase (SGPT)IBA 12/2019 - 03/2015
4	Biomarkers (Surrogate Marker)IBA 02/2018 - 09/2012
4	Neutralizing AntibodiesIBA 01/2017 - 07/2015
3	Peptides (Polypeptides)IBA 01/2021 - 11/2008
3	Amino Acids FDA Link 12/2020 - 01/2008
3	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 03/2015 - 09/2010
2	Antiviral Agents (Antivirals)IBA 03/2022 - 01/2015
2	Chimeric Antigen ReceptorsIBA 10/2021 - 01/2021
2	Therapeutic UsesIBA 10/2021 - 04/2016
2	N-acetyltalosaminuronic acid (NAT)IBA 11/2020 - 01/2019
2	Monoclonal AntibodiesIBA 01/2017 - 04/2016
2	InterferonsIBA 01/2017 - 12/2014
2	Membrane Proteins (Integral Membrane Proteins)IBA 04/2016 - 10/2012
2	Hepatitis B Core AntigensIBA 01/2015 - 12/2014
1	Tenofovir (Viread)FDA Link 03/2022
1	entecavir FDA Link 03/2022
1	human ERBB2 proteinIBA 01/2022
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2022
1	Pharmaceutical PreparationsIBA 12/2021
1	Synthetic Vaccines (Recombinant Vaccines)IBA 12/2021
1	ErbB Receptors (EGF Receptor)IBA 10/2021
1	SARS-CoV-2 spike proteinIBA 12/2020
1	Protein SIBA 12/2020
1	GTP-Binding Proteins (G-Protein)IBA 12/2020
1	Nucleic AcidsIBA 11/2020
1	Viral RNAIBA 11/2020
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 01/2020
1	Hepatitis C AntibodiesIBA 03/2019
1	Hepatitis A AntibodiesIBA 03/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Taurocholic Acid (Sodium Taurocholate)IBA 01/2019
1	hepatitis B hyperimmune globulinIBA 01/2019
1	Internal Ribosome Entry SitesIBA 01/2019
1	Doxycycline (Periostat)FDA LinkGeneric 01/2019
1	Trans-Activators (Trans-Acting Factor)IBA 01/2019
1	Ribavirin (Virazole)FDA LinkGeneric 12/2018
1	GlobulinsIBA 05/2018
1	AlbuminsIBA 05/2018
1	Hepatitis delta Antigens (HDAg)IBA 12/2017
1	Palivizumab FDA Link 01/2017
1	Glycoproteins (Glycoprotein)IBA 01/2017
1	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2014
1	EnzymesIBA 12/2012
1	ImmunosorbentsIBA 12/2012
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2012
1	Estrogens (Estrogen)FDA Link 04/2012
1	AluminumIBA 09/2010
1	hydroxide ionIBA 09/2010
1	Capsid Proteins (Capsid Protein)IBA 07/2010
1	Hemagglutinins (Hemagglutinin)IBA 11/2008
1	Virus ReceptorsIBA 06/2008

Therapy/Procedure

6	Therapeutics 01/2022 - 02/2011
1	Liver Transplantation 12/2018
1	Immunotherapy 01/2017
1	Oncolytic Virotherapy 03/2016
1	Blood Transfusion (Blood Transfusions) 10/2013